EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access

A Case-Control Study of Esomeprazole plus Rebamipide vs. Omeprazole plus Rebamipide on Post-ESD Gastric Ulcers

Maki Bunno, Kyosuke Gouda, Kunihiro Yamahara, Masanori Kawaguchi

Japanese Clinical Medicine · 2013

DOI: 10.4137/jcm.s11320 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Japanese Clinical Medicine, 2013. Verfasst von Maki Bunno und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Saiseikai Wakayama Hospital, Wakayama-City, Japan. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Endoscopic submucosal dissection (ESD) is useful for treating gastric tumors. Several trials have shown the efficacy of 4 or 8 weeks of proton pump inhibitor (PPI) administration for post-ESD ulcers. However, if the size of the post-ESD ulcer is larger than predicted, PPI administration alone might not be sufficient for the ulcer to heal within 4 weeks. There is no report about the efficacy of post-ESD gastric ulcers by esomeprazole. We examined retrospectively the efficacy of a combination therapy of esomeprazole plus rebamipide, a mucosal-protective antiulcer drug, on the acceleration of post-ESD ulcer healing comparing with omeprazole plus rebamipide.

Methods

We reviewed the medical records of patients who underwent ESD for gastric neoplasia. We conducted a case-control study to compare the healing rates within 4 weeks effected by esomeprazole plus rebamipide (group E) and omeprazole plus rebamipide (group O). The sizes of the artificial ulcers were divided into normal-sized or large-sized.

Results

The baseline characteristics did not differ significantly between the two groups except age and sex. Stage S1 disease was observed in 27.6% and 38.7% of patients after 4 weeks of treatment in the group E and O, respectively. In large-sized artificial ulcers, the healing rate of stage S1 in group E is significantly higher than that in group O in 4 weeks.(25% VS 0%: P = 0.02)

Conclusions

The safety and efficacy profiles of esomeprazole plus rebamipide and omeprazole and rebamipide are similar for the treatment of ESD-induced ulcers. In large-sized ulcers, esomeprazole plus rebamipide promotes ulcer healing.

Schlagwörter

Stichwörter der Autor:innen

endoscopic submucosal dissectionesomeprazolegastric neoplasmomeprazolerebamipide

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Saiseikai Wakayama Hospital, Wakayama-City, Japan.

Zitieren

APA

Bunno, M., Gouda, K., Yamahara, K., & Kawaguchi, M. (2013). A Case-Control Study of Esomeprazole plus Rebamipide vs. Omeprazole plus Rebamipide on Post-ESD Gastric Ulcers. Japanese Clinical Medicine. https://doi.org/10.4137/jcm.s11320

Vancouver

Bunno M, Gouda K, Yamahara K, Kawaguchi M. A Case-Control Study of Esomeprazole plus Rebamipide vs. Omeprazole plus Rebamipide on Post-ESD Gastric Ulcers. Japanese Clinical Medicine. 2013. doi:10.4137/jcm.s11320

BibTeX
@article{Bunno2013,
  author = {Bunno, Maki and Gouda, Kyosuke and Yamahara, Kunihiro and Kawaguchi, Masanori},
  title = {A Case-Control Study of Esomeprazole plus Rebamipide vs. Omeprazole plus Rebamipide on Post-ESD Gastric Ulcers},
  journal = {Japanese Clinical Medicine},
  year = {2013},
  doi = {10.4137/jcm.s11320}
}
Kostenlos starten →